EBT Market Purchase Programme

Darktrace PLC
01 November 2023
 

Darktrace plc

1 November 2023

 

EBT Market Purchase Programme

Darktrace plc (DARK.L) (together with its subsidiaries "Darktrace" or the "Group"), a global leader in cyber security AI, today announces that Equiniti Trust (Jersey) Limited (the "Trustee"), as Trustee of the Darktrace Employee Benefit Trust (the "EBT") will commence on or about 1 November 2023 making further market purchases of ordinary shares of £0.01 each in Darktrace ("Shares") for up to 10 million Shares (the "EBT Market Purchase Programme").

Purchases under the EBT Market Purchase Programme are for a maximum aggregate consideration of £25 million (inclusive of brokerage and dealing charges). The EBT Market Purchase Programme will complete on or before 31 December 2023, unless extended by Darktrace (subject to applicable law). Shares purchased under the EBT Market Purchase Programme will be used to satisfy existing, planned and anticipated options and awards under Darktrace's employee share schemes, or as otherwise permissible within the terms of the EBT trust deed.

Contact:

Luk Janssens - Head of Investor Relations, Darktrace

Direct: +44 7811 027918

luk.janssens@darktrace.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Darktrace (DARK)
UK 100

Latest directors dealings